《生命科学》 2014, 26(1): 50-58

阿尔茨海默病免疫治疗的临床研究进展

杨策策，王　涛，肖世富^*

(上海交通大学阿尔茨海默病诊治中心，上海交通大学医学院附属精神卫生中心，上海 200030)

摘　要：摘　要：阿尔茨海默病免疫治疗以淀粉样蛋白Aβ 或tau 蛋白为治疗靶点。通过疫苗刺激产生靶标抗体的主动免疫或直接给予抗体的被动免疫，可减轻AD 病理改变，有望延缓或阻止AD 病程进展。动物研究显示了广阔的治疗前景，临床免疫治疗的部分药物已完成III 期试验，但未达到预期效果。综述近年来免疫治疗AD 的临床研究进展。

New development of clinical trial in immunotherapy for Alzheimer's disease

YANG Ce-Ce， WANG Tao， XIAO Shi-Fu^*

(Alzheimer’s Disease and Related Disorders Center， Shanghai Jiaotong University; Shanghai Mental Health Center， Shanghai Jiaotong University School of Medicine， Shanghai 200030， China)

Abstract: Abstract: Immunotherapy for Alzheimer’s disease has shown that targeting beta amyloid (Aβ) or tau protein with vaccines or antibodies can reduce pathology. Active or passive immunotherapy is expected to slow or stop the progress of AD. Significant advances in preclinical studies have shown strong evidence， but several clinical trials primarily targeting Aβ in phase III have failed. Herein we review primarily the progress of immunotherapy for AD in clinical trials.